Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (1.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (74.1%), Europe (17%) and other (8.9%).

Number of employees : 11 800 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
Innovative Medicines22,12799.6%22,449100.6% +1.46%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
United States16,26973.2%16,64574.6% +2.31%
Europe4,00618%3,81117.1% -4.87%
Other International1,8528.3%1,9938.9% +7.61%
Managers
NameAgeSinceTitle
Daniel O'Day552019Chairman & Chief Executive Officer
Andrew D. Dickinson492019Chief Financial Officer
William A. Lee, Dr.642015Executive Vice President-Research
Merdad V. Parsey, Dr.-2019Chief Medical Officer
George Pratt Shultz, Dr.962006Director-Emeritus
Gayle Edlund Wilson762001Independent Director
John Francis Cogan, Dr.712013Lead Independent Director
Richard J. Whitley, Dr.732008Independent Director
Kevin E. Lofton642009Independent Director
Per Wold-Olsen722010Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,253,724,370 1,247,247,186 99.5% 0 0.0% 99.5%
Shareholders
NameEquities%
The Vanguard Group, Inc. 100,848,581 8.04%
Capital Research & Management Co. (Global Investors) 95,982,319 7.65%
Putnam LLC 83,388,336 6.65%
Capital Research & Management Co. 64,780,000 5.16%
SSgA Funds Management, Inc. 56,805,210 4.53%
Capital Research & Management Co. (International Investors) 56,369,657 4.49%
Capital Research & Management Co. (World Investors) 46,331,318 3.69%
BlackRock Fund Advisors 31,569,860 2.52%
Geode Capital Management LLC 19,882,508 1.59%
Northern Trust Investments, Inc.(Investment Management) 15,554,923 1.24%
Holdings
NameEquities%Valuation
Galapagos NV (GLPG) 16,707,47725.6%3,284,813,948 USD
Allogene Therapeutics, Inc. (ALLO) 7,486,6895.39%320,580,023 USD
Arcus Biosciences, Inc. (RCUS) 8,163,02914.3%201,953,337 USD
Agenus Inc. (AGEN) 11,111,1116.54%43,666,666 USD
HOOKIPA Pharma Inc. (HOOK) 1,667,2687.64%19,373,654 USD
Sierra Oncology, Inc. (SRRA) 348,0173.35%4,211,006 USD
Markets and indexes
- Nasdaq Stock Market
- Nasdaq Global Select Market
- Nasdaq 100 / SP 100, SP 500, Stoxx Americas 100, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  GILD:US
- Reuters Code :  GILD.O
- Datastream Code :  @GILD
Company contact information
Gilead Sciences, Inc.
333 Lakeside Drive
CA 94404 San Mateo, California
États-Unis (les)

Phone : +1 650 574 3000
Fax : +1 650 578 9264
Internet : http://www.gilead.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Gilead Sciences, Inc.
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.5.94%86 319
VERTEX PHARMACEUTICALS23.70%70 548
REGENERON PHARMACEUTICALS63.08%64 438
WUXI APPTEC CO., LTD.65.88%37 073
GENMAB A/S53.09%23 475
BEIGENE, LTD.28.64%19 295
BIONTECH SE103.98%16 460
HUALAN BIOLOGICAL ENGINEERING INC.104.82%14 564
SAREPTA THERAPEUTICS, INC.22.44%12 404
ARGENX SE38.51%11 049
NEUROCRINE BIOSCIENCES, INC.6.24%10 653
ASCENDIS PHARMA A/S1.35%7 502
EXELIXIS, INC.24.06%6 755
BIOCON LIMITED35.04%6 289
ZAI LAB LIMITED91.51%5 971
MIRATI THERAPEUTICS, INC.2.12%5 874
PEPTIDREAM INC.-15.71%5 549
ACCELERON PHARMA INC.73.90%5 530
MYOKARDIA, INC.39.29%5 383
ULTRAGENYX PHARMACEUTICAL INC.96.23%5 077
FORTY SEVEN, INC.142.60%4 599